Brain Tumor Diagnosis & Therapeutics Market by Type (Primary Brain Tumor and Secondary Brain Tumor), by Diagnosis Type (MRI, CT-Scan, Tissue Sampling, PET CT-Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, and EEG), by Therapy (Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Surgery), and by End User (Hospitals, Ambulatory, and Surgical Centers)- Global Opportunity Analysis and Industry Forecast 2024-2030

Brain Tumor Diagnosis & Therapeutics Market Overview

Brain Tumor Diagnosis & Therapeutics Market size was valued at USD 3.4 billion in 2023 and is estimated to reach USD 6.8 billion by 2030, registering a CAGR of 10.7% from 2024-2030. Brain tumor diagnosis & therapeutics market encompass a broad field of medical practices and technologies aimed at detecting and treating tumors in the brain. The diagnosis and treatment of brain tumors includes numerous medical processes of identifying and eradicating brain tumors in people. Diagnosing it involves the use of techniques that produce clear images of the brain organs, this includes MRI, CT and PET scans to discover tumors and assess their properties.

Treatment depends on the nature of the tumor, its location and its degree of malignancy. Some of the commonly used treatments include surgically removal of the tumor and the use of radiations to stop the growth of cancerous cells. The field of brain tumor diagnosis & therapeutics continues to evolve with ongoing R&D in the development of personalized medicine and novel treatment, aiming to improve outcomes for patients affected by these challenging conditions.

Market Dynamics and Trends

The rapidly growing brain tumor incidents worldwide is driven by the increasing geriatric population across the globe.  As people age, the possibility of developing brain tumors also rises, driving the demand for early detection and diagnostic solutions. For instance, as per the National Brain Tumor Society, about 90000 people in the U.S. whereas around 12700 people in the UK suffer from brain and spinal tumor every year. Such prevalence drives the growth for timely identification and treatment and of these conditions, boosting the brain tumor diagnosis & therapeutics market demand.

Moreover, development in healthcare sector, driven by the rising investments by public and private sectors for research and development (R&D) to develop novel medication for the treatment of numerous diseases, including brain tumor, is further boosts the growth of the market.

According to a report from the Centers for Medicare & Medicaid Services (CMS), medical spending in the U.S. reached USD 4.84 trillion in 2023, up from USD 4.50 trillion in 2022. Also, the Government of India allocated USD 107.85 billion for the development of healthcare sector in 2023, up from USD 95.74 billion in 2022. Such growth in the government investment leads to the growing expansion of brain tumor diagnosis industry.

Furthermore, increasing demand for advanced medication due to the advancements in treatment therapies such as gene therapy and stem cell technology are further expected to boost the brain tumor diagnosis & therapeutics market growth.

For instance, in April 2024, the University of California, San Francisco, invested USD 11 million to initiate a clinical trial using gene therapy for the treatment of brain tumors. This significant investment aims towards the development of innovative treatment approaches such as advanced therapies to improve patient outcomes.

However, the high cost of treatment and lack of trained professionals restrains the growth of the brain tumor diagnosis and therapeutics market.

On the contrary, the integration of artificial intelligence (AI) with diagnosis technologies is anticipated to create ample growth opportunities for the market in the coming years. AI is anticipated to revolutionize the treatment of brain tumors by enhancing diagnostics and optimizing therapy delivery, leading to earlier and more accurate diagnoses, enhancing patient outcomes and quality of life.

Market Segmentation and Scope of the Study

The brain tumor diagnosis & therapeutics market report is segmented on the basis of type, diagnosis type, therapy, end user, and region. On the basis of type, the market is classified into Primary Brain Tumor and Secondary Brain Tumor. On the basis of diagnosis type, the market is divided into MRI, CT-Scan, tissue sampling, PET CT-Scan, cerebral arteriogram, lumbar puncture, molecular testing, and EEG. On the basis of therapy, the market is segmented into chemotherapy, gene therapy, immunotherapy, radiation therapy, targeted therapy, and surgery. On the basis of end user, the market is classified into hospitals, ambulatory, and surgical centers. Regional breakdown and deep analysis of each segment are included for North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America dominates the brain tumor diagnosis & therapeutics market share and is expected to continue dominating the industry during the forecasted period. This is attributed to the growing prevalence of brain tumor incidents coupled with rising awareness regarding advanced diagnosis facilities among the population in this region.

For instance, in February 2022, American Society of Clinical Oncology (ASCO) reported that an estimated 25,050 adults (14,170 men and 10,880 women) and about 4,170 children under the age of 15 in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord.

Moreover, the rising numbers of therapy trials by healthcare institutes along with expanding R&D activities for the treatment of brain tumours is expected to boost the growth of the brain tumor diagnosis & therapeutics market in this region.

For instance, in April 2024, Pfizer announced a significant progress in its efforts to accelerate breakthrough cancer treatments, with a focus that includes therapies for brain tumors. The company is advancing innovative treatments through a series of clinical trials and research initiatives aimed at improving patient outcomes. Notable developments include new targeted therapies and immunodiagnostics designed to more effectively combat brain tumors and other cancers. 

On the other hand, Europe is expected to show a steady rise in brain tumor diagnosis & therapeutics market over the forecast period. This is attributed to the increasing incidents of neurological disorder and increasing aging population in countries such as the Italy, France, and other European countries. 

As stated by the World Health Organization, the number of new cancer and neurological disorders in Italy reached 436 thousand in 2022 leading to 193 thousand deaths. Such rise in the number of neurological disorders in Europe is driving the demand for brain tumor diagnosis & therapeutics in this region.

Moreover, the rising collaboration among numerous European countries for the development of healthcare sector and to support R&D initiatives in the field of brain tumour and cancer diagnosis further boosts the market growth in this region. 

For instance, as stated by the Government of UK, Cancer Research UK and France’s Institute National Du Cancer (INCa) announced a new partnership to support world-class cancer researchers through the global Cancer Grand Challenges initiative, aiming for international collaboration and transformational research. Such initiatives by the government and major bio-pharma companies are driving the growth of the market in this region.

Competitive Landscape

The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, Novartis AG, Karyopharm Therapeutics, Koninklijke Philips N.V., Canon Medical Systems Corporation, Lantern Pharma, and others. 

These market players are adopting various strategies such as product launch, investments in R&D activities, and collaborations to early detection of brain cancer to remain dominant in the brain tumor diagnosis and therapeutic market. 

For instance, in May 2024, Amgen Inc announced its advancements in the diagnosis and treatment of various cancers, including new approaches in brain tumor diagnosis. This research aims to improve early detection and enhance therapeutic outcomes for patients with brain tumors, leveraging cutting-edge technologies and novel biomarkers.

Moreover, in May 2024, AstraZeneca Plc launched Enhertu, an antibody-drug conjugate, that received FDA approval for the treatment of solid tumors. Through this launch, the company aims to enhance treatment efficacy and improve survival rates and quality of life for patients.

Also, in November 2022, Northwest Biotherapeutics’ launched DCVax vaccine to treat deadly cancerous brain tumours. The DCVax vaccination improves the immune response to fight the tumor cells, enhancing the overall patient outcome. 

Moreover, in October 2022, Koninklijke Philips N.V. announced two new advancements in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application allows the use of MR as primary imaging modality for radiotherapy in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received FDA clearance and is commercially available in the U.S.

Key Benefits

• The report provides quantitative analysis and estimations of the brain tumor diagnosis and therapeutic market from 2024 to 2030, which assists in identifying the prevailing industry opportunities.

• The study comprises a deep-dive analysis of the current and future brain tumor diagnosis and therapeutic market to depict prevalent investment pockets in the industry.

• Information related to key drivers, restraints, and opportunities and their impact on the brain tumor diagnosis and therapeutic market is provided in the report. 

• Competitive analysis of the key players, along with their market share is provided in the report.

• SWOT analysis and Porters Five Forces model is elaborated on the study.

• Value chain analysis in the market study provides a clear picture of roles of stakeholders.

Brain Tumor Diagnosis and Therapeutic Market Key Segments

By Type

• Primary Brain Tumor and 

• Secondary Brain Tumor

By Diagnosis Type

• MRI, CT-Scan

• Tissue Sampling

• PET CT-Scan

• Cerebral Arteriogram

• Lumbar Puncture

• Molecular Testing

• EEG

By Therapy

• Chemotherapy

• Gene Therapy

• Immunotherapy

• Radiation Therapy 

• Targeted Therapy

• Surgery

By End User

• Hospitals

• Ambulatory

• Surgical Centers

By Region

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The UK

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia Pacific 

• RoW

  • Latin America

  • Middle East 

  • Africa

REPORT SCOPE AND SEGMENTATION

Test